Abstract
Dermatofibrosarcoma is a rare low-grade sarcoma characterized in more than 90% of cases by (17q22; 22q13) translocation leading to a fusion transcript COL1A1-PDGFB. Surgical therapy is the standard of care; however, tyrosine-kinase inhibitors targeting PDGFR are of interest in unresectable or rare metastatic tumors. Imatinib mesylate has been approved in this indication and research is going on with other inhibitors.
Résumé
La tumeur de Darier-Ferrand ou dermatofibrosarcome protuberans est un sarcome de malignité intermédiaire de cytogénétique simple caractérisé par la présence d’une translocation chromosomique aboutissant à la fusion des chromosomes 17q22 et 22q13 et à l’expression d’une protéine de fusion COL1A1-PDGFgB qui exercerait un effet autocrine ou paracrine lors de son interaction avec le récepteur au PDGFgB présent à la surface des cellules tumorales. Son traitement repose sur la chirurgie complète, ou parfois dans des formes localement avancées, ou inopérables, ou transformées en sarcome de plus haut grade, ou métastatique sur des thérapies ciblées telles que l’imatinib mésylate (Glivec®) qui a aujourd’hui l’AMM dans cette indication, ou d’autres molécules plus récentes telles que le pazopanib qui est actuellement évalué dans le cadre d’un essai national.
Similar content being viewed by others
Références
Farma JM, Ammori JS, Zager JS, et al. (2010) Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 17: 2112–2118
Foroozan M, Sei JF, Amini M, et al. (2012) Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol 148(9): 1055–1063
Greco A, Roccato E, Miranda C, et al. (2001) Growth-inhibitory effect of STI 571 on cells transformed by the COL1A1/ PDGFB rearrangement. Int J Cancer 92: 354–360
Kerob D, Pedeutour F, Leboeuf C, et al. (2008) Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 26(10): 1757–1759
Kerob D, Porcher R, Verola O, et al. (2010) Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 16: 3288–3295
Labropoulos SV, Flechter JA, Oliveira AM, et al. (2005) Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anti Cancer Drugs 16: 461–466
Lemm D, Mügge LO, Mentzel T, Höffken KJ 2009 Current treatment options in dermatofibrosarcoma protuberans. Cancer Res Clin Oncol 135(5): 653–665. doi: 10. 1007/s00432-009-0550-3
Malhotra B, Schuetze SM (2012) Dermatofobrisarcoma protuberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Curr Opin Oncol 24: 419–424
McArthur GA, Demetri GD, van Oosterom A, et al. (2005) Molecular and clinical analysis of locally advanced dermatofiborsarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 23: 866–873
Rubin BP, Schuetze SM, Eary JF, et al. (2002) Molecular targeting of platelet derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20: 3586–3591
Rutkowski P, Debiec-Rychter M, Nowecki ZI, et al. (2011) Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 25: 264–270
Rutkowski P, Van Glabbeke M, Rankin CJ, et al. (2010) Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28: 1772–1779
Schimizu A, O’Brien KP, Sjoblom T, et al. (1999) The DFSP associated collagen type alpha/platelet derived growth factor B-chain fusion gene generates a transforming protein that is processed to functionnal PDFGBB. Cancer Res 59: 3719–3723
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Pagès, C., Kérob, D. & Lebbé, C. Thérapies ciblées et dermatofibrosarcome de Darier et Ferrand. Oncologie 15, 97–100 (2013). https://doi.org/10.1007/s10269-013-2251-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-013-2251-4